Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Choosing a safe and effective anticoagulant is complicated when patient is obese
+Print Archive
Practice
Choosing a safe and effective anticoagulant is complicated when patient is obese
Wednesday 29 January 2020, 01:00 AM

Treatment failure is a concern when using direct-acting oral anticoagulants in patients with high body weight
PHARMACOTHERAPY
It is likely you will come across obese patients requiring anticoagulation. This article summarises international studies and guidelines, to help you determine whether a direct-acting oral anticoagulant or vitamin K antagonist is the best option.
Linda Bryant and Pauline McQuoid
Key points, Warfarin is the anticoagulant of choice for obese patients.
Direct-acting oral anticoagulants should be avoided in patients with high body weight (B
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.